Russian journal of anaesthesiology and reanimatology 2, 2019 Клинические рекомендации фар
жүктеу/скачать 0,76 Mb. Pdf көрінісі
|
Anestesiolog 2019 02 005
| brinolysis
. 2007;18(7):589-593. 118. Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology. 2007;12(1):55-62. 119. Shah N, Chong S, Yusoff S, Mazlan M, et al. Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven- year single-centre experience. BMC Hematol. 2018;18:34. 120. Ahonen J. The role of recombinant activated factor VII in obstetric hemor- rhage. Curr Opin Anaesthesiol. 2012;25(3):309-314. 121. Kalina M, Tinkoff G, Fulda G. Massive postpartum hemorrhage: recombi- nant factor VIIa use is safe but not effective. Del Med J. 2011;83(4):109-113. 122. Dutta T, Verma S. Rational Use of Recombinant Factor VIIa in Clinical Practice. Indian J Hematol Blood Transfus. 2014;30(2):85-90. 123. Bolliger D, Mauermann E, Tanaka K. Thresholds for Perioperative Administra- tion of Hemostatic Blood Components and Coagulation Factor Concentrates: An Unmet Medical Need. J Cardiothorac Vasc Anesth. 2015;29(3):768-776. 124. Knight M, Fitzpatrick K, Kurinczuk J, Tuffnell D. Use of recombinant factor VIIa in patients with amniotic fluid embolism. Anesthesiology. 2012;117:423. 125. Neb H, Zacharowski K, Meybohm P. Strategies to reduce blood product uti- lization in obstetric practice. Curr Opin Anaesthesiol. 2017;30(3):294-299. 126. Godier A, Greinacher A, Faraoni D, Levy J, Samama M. Use of factor con- centrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(1):170-174. 127. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno G, Tar- gher G, Lippi G. The use of recombinant activated FVII in postpartum hem- orrhage. Clin Obstet Gynecol. 2010;53(1):219-227. 128. Zarychanski R, Abou-Setta A, Kanji S, Turgeon A, et al. Canadian Critical Care Trials Group. The efficacy and safety of heparin in pa- tients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):511-518. 129. Bain E, Wilson A, Tooher R, Gates S, Davis L, Middleton P. Prophylax- is for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014;(2):CD001689. 130. Villani M, Ageno W, Grandone E, Dentali F. The prevention and treatment of venous thromboembolism in pregnancy. Expert Rev Cardiovasc Ther. 2017;15(5):397-402. 131. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of dissemi- nated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care . 2014;2(1):15. 132. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845-854. 133. Squizzato A, Hunt B, Kinasewitz G, Wada H, et al. Supportive management strategies for disseminated intravascular coagulation. An international con- sensus. Thromb Haemost. 2016;115(5):896-904. 134. Venugopal A. Disseminated intravascular coagulation. Indian J Anaesth. 2014;58(5):603-608. 135. Yatabe T, Inoue S, Sakamoto S, Sumi Y, et al. The anticoagulant treatment for sepsis induced disseminated intravascular coagulation; network meta- analysis. Thromb Res. 2018;171:136-142. 136. Hayakawa M, Ono K. A summary of the Japan septic disseminated intravas- cular coagulation study. Acute Med Surg. 2018;5(2):123-128. 137. Yamakawa K, Umemura Y, Hayakawa M, Kudo D, et al. Japan Septic Dis- seminated Intravascular Coagulation (J-Septic DIC) study group. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20(1):229. 138. Rhodes A, Evans L, Alhazzani W, Levy M, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. жүктеу/скачать 0,76 Mb. Достарыңызбен бөлісу:
|